GlaxoSmithKline PLC ADR (GSK)

38.35
+0.44(+1.16%)
After Hours
38.36
+0.01(+0.03%)
- Real-time Data
  • Volume:
    3,004,116
  • Bid/Ask:
    38.35/38.39
  • Day's Range:
    38.06 - 38.42

GSK Overview

Prev. Close
37.91
Day's Range
38.06 - 38.42
Revenue
44.32B
Open
38.1
52 wk Range
33.26 - 43.18
EPS
2.92
Volume
3,004,116
Market Cap
95.34B
Dividend (Yield)
2.65 (6.98%)
Average Vol. (3m)
5,721,509
P/E Ratio
13.14
Beta
0.69
1-Year Change
-8.03%
Shares Outstanding
5,029,983,667
Next Earnings Date
Jul 28, 2021
What is your sentiment on GlaxoSmithKline PLC ADR?
or
Market is currently closed. Voting is open during market hours.

GlaxoSmithKline PLC ADR News

GlaxoSmithKline PLC ADR Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyStrong BuyStrong BuySell
Technical IndicatorsStrong SellStrong BuyStrong BuyStrong BuySell
SummaryNeutralStrong BuyStrong BuyStrong BuySell

GlaxoSmithKline PLC ADR Company Profile

GlaxoSmithKline PLC ADR Company Profile

Industry
Major Drugs
Employees
94066

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Read More
  • Bullish consolidation. Next move coming.
    0
    • a company that makes Geritol, cant be all bad
      0
      • i have held a full position in this stock through very rocky periods because of the dividend. stock getting a nice bump today as it was reported that hedge fund Elliott Management has taken a multi-billion pound stake. cant wait for it to go over 40 again; in spite of the weak CEO.
        1
        • when is this horrible female CEO stepping down? Trial failure over trial failure. Disastrous
          2
          • don't know, but stock is getting a nice bump today in premarket
            0
          • What does it have to do with female? Should double my position.
            0
          • What does it have to do with being a female? You are talking like all male ceos are great at their job.
            0
        • I hold it for one reason and that reason is dividend. Lovely free cash. If they keep increasing dividends at same pace , dividend yield will be 10 percent in few years , this is madness lol. Normally you dont get same return for your investment even if you invest in junk bonds of horribly rated countries. If GSK dont go bankrupt,I will consider retiring very early . Lol
          0
          • did you account for currency? not an American company
            0
          • Mark Jannettydividends are in usd currency. At the least it is usd at the site that i use. Exact same number that i receive.
            0
          • Mark JannettyIf you bought the ADR stock. Your dividends are going to be paid in USD. Otherwise you have to buy stock from FTSE
            0
        • Stock is a bargain and people will "safe play" with healthcare stocks. This will lift GSK near to 40$
          1
          • You are misleading people . There is no significant growth in revenue for long time. Actually even worse than past revenues. But dividend yield is just going up. I own stock too, but i don’t mislead people like you. As long as they keep paying higher dividends while revenue is struggling. This stock is not cheap or bargain.
            0
        • 1.2323 x 2020 Q3 divi = Q4 divi0.636668 per share . Lets assume price of share is 40$Annual rate of Q4 is 6.367 percent and price is not 40$ guys , current price is 36 so annual rate is 7.074 percentDespite the fact that earnings are worse than expected. And you expect this share to rally? Just enjoy your divi lol
          0
          • By the way latest dividend is wrong here , i just checked from GSK’s own site and my account report , so the numbers that i gave you are correct
            0
        • Vaccine did not boost price of JJ in an amazing way, i also hold JJ. As long as GSK keeps paying massive dividends, i do not expect a rally. I am not complaining, i bought this stock for huge divi. An increase in price could be good too, but lets be realist , huge divi plus bad earnings keeps stock price low. If you are seeking profit from price change , it isnt good one to buy.
          0
          • We might follow Aprill last year $41, plus news on vaccine relese in partnership...
            0
            • I'm on the same page with you. Current price is a bargain. I think it'll go 37-38-39$ and consolidates after then. 40$ is hard to pass but it is possible.
              0
          • Let's squeeze the shorts!
            0
            • Nice W forming
              1
              • Travelling back to 39-40$, the question is, will it go further
                0
                • in ur dreams
                  1
                • Yes, and I think my dreams will come true :)
                  0
              • joint effort and 1 company takes off and gsk goes down. say what?
                0
                • 🚀🚀🚀
                  0
                  • back to the 39-40$ range.
                    0
                    • They keep increasing dividends despite the fact that earnings decrease. I am not optimist about price, enjoy your massive divi
                      0
                    • YUNUS EMRE ALTUNin case of movement down, I will but another for 26,7
                      0
                    • sure hope it heads back to the 39-40 range Jarkko, as I have held a lot of shares for a couple of years now...
                      0
                  • Prove connecting Wuhan laboratory owned GSK with Pfizer covid https://www.gsk.com/en-gb/media/press-releases/gsk-completes-transaction-with-pfizer-to-form-new-world-leading-consumer-healthcare-joint-venture/
                    0
                    • Ok tinfoil hat
                      0
                  • They are connected with a laboratory in Wuhan City and Pfizer
                    0
                    • Divi very lovely but i cant say same for price
                      0
                      • Cheap atm
                        0
                        • complete overreaction, but recovery may take longer than you think as positive sentiment has been damaged.
                          0
                          • overreaction will rebound shortly 40$ solid
                            1
                            • Lol it is fup
                              0
                              • inline earnings and its down 4%.whats reason
                                0
                                • UK Shares under-perform (yesterday it was the similar situation with BP). I don't know if UK lock-downs or BrExit affected the price... but the price is good to buy
                                  0
                              • Real value is over 40$, before pandemic price was almost 50€, so with current biotech/vaccine/etc.. boom will drive price there eventually.
                                0
                                • It is paying heavy dividends , i m not that much optimist about price , enjoy your dividend.
                                  0
                                • The long term debt is huge... don't know how can they manage that
                                  0
                              • Price is way below estimates, so it cheap atm?!
                                0
                                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.